Clinical Studies for Hematology/Oncology

For more information, visit our Hematology/Oncology Program

Return to Non-Cancer Program Name Search

Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)

Brief Title: Abelacimab vs placebo in Afib

Brief Summary: A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

PI: Rushad Patell, MD

Group: Hematology Oncology

Study Start: 6/2/2025

End: 12/30/2027

Gender: All

Age Range: 65 Years to 100 Years

Recruit Healthy Volunteers: No

ID: NCT05712200

For info regarding 2025P000250 please contact Rushad Patell at 617-667-2100 or rpatell@bidmc.harvard.edu

View on ClinicalTrials.Gov

Clinical Trials Displayed: 1